BETA

IPO registrations (S-1, F-1) · Registrants

XERIS PHARMACEUTICALS INC

SEC CIK
1346302 · filings on EDGAR ↗
Registration
Form S-1, first filed 2018-05-24, last 2019-02-11; 2 initial registrations, 2 amendments
Outcome
Final prospectus filed 2018-06-21; declared effective 2018-06-20
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
180 NORTH LASALLE STREET, SUITE 1600, Chicago, IL 60601
EIN
20-3352427
EDGAR entity type
operating
Insiders and CEO pay
XERIS PHARMACEUTICALS INC on the corporate pages

Offering terms

Proposed price range
$14.00–$16.00 per share (S-1/A filed 2018-06-14)
Final price
$15.00 per share, within the range (424B4 filed 2018-06-21, an initial public offering)
Shares sold
5,700,000
Gross proceeds
$85,500,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol XERS
Lead underwriters
Jefferies (2,166,000 shares); Leerink Partners (1,938,000 shares); RBC Capital Markets (1,140,000 shares); Mizuho (456,000 shares)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 11

FiledFormWhat it isName as filedEDGAR
2018-05-24S-1S-1 (registration)XERIS PHARMACEUTICALS INC0001193125-18-173711 ↗
2018-06-11S-1/AS-1/A (amendment)XERIS PHARMACEUTICALS INC0001193125-18-188635 ↗
2018-06-14S-1/AS-1/A (amendment)XERIS PHARMACEUTICALS INC0001193125-18-193093 ↗
2018-06-20S-1MEFS-1MEF (added securities)XERIS PHARMACEUTICALS INC0001193125-18-198199 ↗
2018-06-20EFFECTEFFECT (declared effective)XERIS PHARMACEUTICALS INC9999999995-18-001558 ↗
2018-06-21424B4424B4 (final prospectus)XERIS PHARMACEUTICALS INC0001193125-18-199679 ↗
2019-02-11S-1S-1 (registration)XERIS PHARMACEUTICALS INC0001193125-19-033935 ↗
2019-02-13S-1MEFS-1MEF (added securities)XERIS PHARMACEUTICALS INC0001193125-19-038611 ↗
2019-02-13EFFECTEFFECT (declared effective)XERIS PHARMACEUTICALS INC9999999995-19-000241 ↗
2019-02-14424B4424B4 (final prospectus)XERIS PHARMACEUTICALS INC0001193125-19-041206 ↗
2019-08-21EFFECTEFFECT (declared effective)XERIS PHARMACEUTICALS INC9999999995-19-001941 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2018-06-14S-1/Aregistration statement$14.00–$16.005,000,000-Nasdaq XERS4primary document; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 4document ↗
2018-06-21424B4final prospectus$15.005,700,000$85,500,000Nasdaq XERS4primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
BORMANN-KENNEDY BARBARA-JEAN ANNEDirector52018–2021
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)TenPercentOwnerOther62018–2019
Deerfield Mgmt III, L.P.TenPercentOwnerOther62018–2019
Deerfield Mgmt L.P.TenPercentOwnerOther62018–2019
Deerfield Private Design Fund III, L.P.TenPercentOwnerOther62018–2019
Deerfield Special Situations Fund, L.P.TenPercentOwnerOther62018–2019
Deutsch Barry M.OfficerChief Financial Officer; See Remarks102018–2021
Edick Paul RDirector,OfficerChief Executive Officer; See Remarks122018–2021
Flynn James ETenPercentOwnerOther62018–2019person page Fuzzy
Green JeremyTenPercentOwner32018–2019
HALKUFF DAWNDirector52018–2021
JOHNSON KENNETH ERLANDOfficerSee Remarks122018–2021
Palmetto Partners 2014, LPTenPercentOwner42018
Palmetto Partners 2015, LPTenPercentOwner42018
Palmetto Partners, Ltd.TenPercentOwner42018
PERSKY MARLADirector52018–2021
PRESTRELSKI STEVENOfficerChief Scientific Officer; See Remarks172018–2021
Redmile Group, LLCTenPercentOwner32018–2019
RIGBY JONATHANDirector22018–2019
Schmid John P.Director52018–2021
Shannon John Patrick JrOfficerSee Remarks132018–2021
SHERMAN JEFFREY WDirector52018–2021person page Fuzzy
Hecht BethOfficerSee Remarks132019–2021
Thierer MarkDirector32019–2020
Pieper StevenOfficerChief Financial Officer; See Remarks32021

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2017-05-22XERIS PHARMACEUTICALS INCPharmaceuticals$44,999,999$30,050,443221
2016-01-11XERIS PHARMACEUTICALS INCPharmaceuticals$49,999,995$45,005,982482
2014-09-29XERIS PHARMACEUTICALS INCOther Technology$14,874,990$7,274,592561

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationXeris Pharmaceuticals, Inc.ILState business registriesname and state
Business registrationXERIS PHARMACEUTICALS, INC.ILState business registriesEIN (EXACT, as the state registration reports it)
Business registrationXERIS PHARMACEUTICALS, INC.ILState business registriesname and state
Business registrationXERIS PHARMACEUTICALS, INC.ILState business registriesname and state
Business registrationXERIS PHARMACEUTICALS, INC.ILState business registriesname and state
Business registrationXERIS PHARMACEUTICALS, INC.ILState business registriesname and state
Business registrationXERIS PHARMACEUTICALS, INC.ILState business registriesname and state
Form D issuerXERIS PHARMACEUTICALS INCILForm D private offeringsCIK (EXACT)
Lobbying clientXERIS PHARMACEUTICALS, INC.ILFederal lobbying (LDA)name and state
Paying companyXeris Pharmaceuticals, Inc.ILOpen Payments (drug and device company payments)name and state
Patent assigneeXERIS PHARMACEUTICALS, INC.ILPatents (USPTO)name and state
SEC filerXERIS PHARMACEUTICALS INCSEC filers (EDGAR)CIK (EXACT)
Trademark ownerXeris Pharmaceuticals, Inc.ILTrademarks (USPTO)name and state
Form 5500 plan sponsorXERIS PHARMACEUTICALS, INC.EIN (EXACT)
Person pageJames E FlynnPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther)
Person pageJeffrey W ShermanPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, IL first:

More with this interest.

In other datasets, the same topic (Health) in IL:

Interests: Pharmaceutical Preparations · Health